Second Long-Acting Antipsychotic Sampling Program Cleared By OIG Advisory Opinion
Executive Summary
The second nearly identical advisory opinion that allows free samples of long-acting antipsychotics to certain hospitals without fear of kickback violations shows inefficiencies of the HHS OIG system for clarifying its fraud and abuse authorities.
You may also be interested in...
Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub
Teva maintains that the clinical data package looks sounds for it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product, as the firms look to muscle in on the multi-billion-dollar LAI schizophrenia market next year.
Long-Acting Antipsychotic Sampling Program In Hospitals Cleared By OIG Advisory Opinion
Sample program focuses only on inpatient use and in hospitals that do not accept Prescription Drug Marketing Act-compliant trial units. By improving adherence, program could lower federal health care costs over time, Office of Inspector General suggests.
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.